Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis

Journal of Dermatological Treatment

Volumn 18, Issue 2, 2007, Pages 88-96

  Ratnavel, Ravi C ^a   Squire, Ruth A ^b   Boorman, Graham C ^c  

^a STOKE MANDEVILLE HOSPITAL   (United Kingdom)

^b PPD Development   (United Kingdom)

^c Stiefel International R and D   (United Kingdom)

Author keywords

Antifungal shampoos; Ciclopirox olamine; Ketoconazole; Seborrhoeic dermatitis

Indexed keywords

CICLOPIROXOLAMINE; KETOCONAZOLE; PLACEBO; SEBIPROX; SHAMPOO; STIEPROX; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCALP; SCHOOL CHILD; SEBORRHEIC DERMATITIS; SKIN BURNING SENSATION; SKIN IRRITATION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; DERMATITIS, SEBORRHEIC; DOUBLE-BLIND METHOD; HAIR PREPARATIONS; HUMANS; KETOCONAZOLE; MIDDLE AGED; PYRIDONES; SCALP DERMATOSES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34249077893     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/16537150601092944     Document Type: Article

References (23)

1. Shuster S. Dandruff, seborrhoeic dermatitis and Pityrosporum ovale. Cosmet Toiletries. 1988;103:87-91.
2. Hay RJ, Graham-Brown RAC. Dandruff and seborrhoeic dermatitis: Causes and management. Clin Exp Dermatol. 1997;22:3-6.
3. Gueho E. Re-evaluation of the genus Malassezia by means of electron microscopy and genome comparison. Bull Soc Fr Mycol Med. 1988;17:245-54.
4. McGinley KJ, Leyden JJ, Marples BN, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff and seborrhoeic dermatitis. J Invest Dermatol. 1975;64:410-15.
5. Roberts SOB. Pityriasis versicolor: A clinical and mycological investigation. Br J Dermatol. 1969;81:351-6.
6. Ford GP, Farr PM, Ive FA, Shuster S. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol. 1984;111:603-7.
7. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: Treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695-700.
8. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol. 1984;111:235-42.
9. Goudard M, Regli P, Lubrano N. In-vitro antifungal spectrum of ciclopirox olamine. Pathol Biol (Paris). 1989;37:621-3.
10. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs. 1985;29:330-41.
11. Przekop PA, Lee AA, Bailey SC, Kurtz ES. Ciclopirox olamine, an antifungal modulator of neutrophil function and infiltrate in cutaneous inflammation. J Invest Dermatol. 1994;102:593.
12. Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184:275-80.
13. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat. 1998;9:157-62.
14. Amos HE, MacLennan AI, Boorman GC. Clinical efficacy of Polytar AF (Fongitar) and Nizoral scalp treatments in patients with dandruff/seborrhoeic dermatitis. J Dermatol Treat. 1994;5:127-30.
15. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing Ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat. 2002;13:51-60.
16. Davies DB, Boorman GC, Shuttleworth D. Comparative efficacy of shampoos containing coal tar (4.0% w/w; Tarmed™), coal tar (4.0% w/w) plus ciclopirox olamine (1.0% w/w; Tarmed™ AF) and ketoconazole (2.0% w/w; Nizoral®) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat. 1999;10:177-83.
17. European Agency for the Evaluation of Medicinal Products, ICH Topic E9: Statistical Principles for Clinical Trials. London, March 1998.
18. White JW Jr. Localized Eczematous Disease. In: Sams WM Jr, Lynch PJ, editors. Principles and practice of dermatology. 2nd ed, New York: Churchill Livingstone, 1996. p. 441-5.
19. Berger RS, Stoner MF, Hobbs ER, Hayes TJ, Boswell RN. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol. 1987;17:746-51.
20. Smith KJ, Skelton HG, Yeager J, Ledsky R, McCarthy W, Baxter D, et al. Cutaneous findings in HIV-1-positive patients: A 42-month prospective study. Military Medical Consortium of the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol. 1994;31:746-54.
21. Ashbee HR, Evans EGV. Immunology of diseases associated with Malassezia species. Clin Microbiol Rev. 2002;15:21-57.
22. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-63.
23. Faergemann J, Bergbrant I-M, Dohsé M, Scott A, Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: Characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144:549-56.